Key points are not available for this paper at this time.
To the Editor: The use of sunitinib, an inhibitor of the split-kinase-domain family of receptor tyrosine kinases (including vascular endothelial growth factor receptor types 1 and 21), has been ass...
Azizi et al. (2008) studied this question.